18F-fluorodeoxyglucose PET-CT provides significant incremental value beyond conventional criteria for predicting response to cardiac resynchronization therapy in nonischemic cardiomyopathy.
Does 18F-fluorodeoxyglucose PET-CT improve the prediction of response to cardiac resynchronization therapy in patients with nonischemic cardiomyopathy compared to conventional criteria?
18F-FDG PET-CT may serve as a useful adjunct to conventional criteria for refining patient selection for cardiac resynchronization therapy in nonischemic cardiomyopathy.
Tasa de eventos absoluta: 0% vs 0%
PET-CT provides significant incremental value beyond conventional electrical and echocardiographic criteria and may serve as a useful adjunct in refining patient selection for CRT.
Kumar et al. (Thu,) reported a other. 18F-fluorodeoxyglucose PET-CT provides significant incremental value beyond conventional criteria for predicting response to cardiac resynchronization therapy in nonischemic cardiomyopathy.